-
Posted by
Two Blokes Jul 15 -
Filed in
Stock
-
1 view
ATLANTA, July 15, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding Biohaven's business, operations, and prospects, including allegations that: (i) troriluzole's regulatory prospects as a treatment for spinocerebellar ataxia, and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; and (iii) all of the foregoing, once revealed, was likely to have a significant negative impact on Biohaven's business and financial condition.
